Walter Ageno
A5081041579- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Blood Coagulation and Thrombosis Mechanisms
- Acute Ischemic Stroke Management
- Central Venous Catheters and Hemodialysis
- Acute Myocardial Infarction Research
- Diagnosis and Treatment of Venous Diseases
- Antiplatelet Therapy and Cardiovascular Diseases
- Liver Disease and Transplantation
- Cardiac Arrhythmias and Treatments
- Case Reports on Hematomas
- Cerebral Venous Sinus Thrombosis
- COVID-19 Clinical Research Studies
- Cardiac tumors and thrombi
- Heparin-Induced Thrombocytopenia and Thrombosis
- Intracerebral and Subarachnoid Hemorrhage Research
- COVID-19 and healthcare impacts
- Vitamin K Research Studies
- Blood Pressure and Hypertension Studies
- Health Systems, Economic Evaluations, Quality of Life
- Ultrasound in Clinical Applications
- Liver Disease Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Pulmonary Hypertension Research and Treatments
- Lipoproteins and Cardiovascular Health
University of Insubria
2016-2025
Ospedale Regionale di Bellinzona e Valli
2024-2025
Ospedale di Circolo e Fondazione Macchi
2011-2024
Ente Ospedaliero Cantonale
2024
Aziende Socio Sanitarie Territoriale dei Sette Laghi
2018-2024
Laboratoire Lorrain de Recherche en Informatique et ses Applications
2023
University of Pisa
2021
University of Naples Federico II
2020
Brigham and Women's Hospital
2018-2020
Harvard University
2018-2020
Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing best management strategies for an individual patient a given condition. their recommendations should facilitate decision making daily practice. However, final decisions concerning must be made by responsible professional(s) consultation caregiver as appropriate.
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their publication.The is not responsible in event any contradiction, discrepancy and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical...
We investigated the efficacy of rivaroxaban, an orally active direct factor Xa inhibitor, in preventing venous thrombosis after total knee arthroplasty.In this randomized, double-blind trial, 2531 patients who were to undergo arthroplasty received either oral 10 mg once daily, beginning 6 8 hours surgery, or subcutaneous enoxaparin, 40 12 before surgery. The primary outcome was composite any deep-vein thrombosis, nonfatal pulmonary embolism, death from cause within 13 17 days Secondary...
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), occurs in ∼1 to 2 individuals per 1000 each year, corresponding ∼300 000 600 events the United States annually.These evidence-based guidelines from American Society of Hematology (ASH) intend support patients, clinicians, others decisions about treatment VTE.ASH formed a multidisciplinary guideline panel balanced minimize potential bias conflicts interest. The McMaster University GRADE Centre...
In patients with idiopathic deep venous thrombosis, continuing anticoagulant therapy beyond three months is associated a reduced incidence of recurrent thrombosis during the period therapy. Whether this benefit persists after discontinued controversial.
About 20% of patients with unprovoked venous thromboembolism have a recurrence within 2 years after the withdrawal oral anticoagulant therapy. Extending anticoagulation prevents recurrences but is associated increased bleeding. The benefit aspirin for prevention recurrent unknown.
Whether an episode of venous thromboembolism (VTE) was unprovoked or provoked by environmental (or acquired) risk factor and, if it provoked, whether the provoking transient persistent, has important prognostic and treatment implications 1.Iorio A. Kearon C. Filippucci E. Marcucci M. Macura Pengo V. Siragusa S. Palareti G. Risk recurrence after a first symptomatic factor: systematic review.Arch Intern Med. 2010; 170: 1710-1716Crossref PubMed Scopus (2) Google Scholar, 2.Kearon Akl E.A....
Early hemorrhagic transformation (HT) is a complication of ischemic stroke but its effect on patient outcome unclear. The aims this study were to assess: (1) the rate early HT in patients admitted for stroke, (2) correlation between and functional at 3 months, (3) risk factors HT.Consecutive with included prospective 4 centers. was assessed by CT examination performed day 5+/-2 after onset. Study outcomes 3-month mortality or disability. Disability using modified Rankin score (> = indicating...
Background: The optimal duration of oral anticoagulant treatment after a first episode pulmonary embolism remains uncertain. Objective: To evaluate the long-term clinical benefit extending 3-month course therapy to 6 months (pulmonary associated with temporary risk factors) or 1 year (idiopathic embolism) in patients embolism. Design: Multicenter randomized study independent, blinded assessment outcome events. Setting: 19 Italian hospitals. Patients: 326 who had 3 without experiencing...
GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns patients newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non–vitamin K antagonist oral anticoagulant (NOAC), became available. This study sought to describe phase baseline data and compare these pre-NOAC era collected during 1. During 2,...